No takes yet. Share an insight, caveat, or question.
Analysis identifies risk score for 30-day morbidity and readmission in lung cancer patients post-neoadjuvant therapy, suggesting improved patient management.
A 2025 study studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: